Viyash Scientific Limited has informed the Exchange about Transcript
VIYASH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Viyash Scientific reported its strongest quarter ever with Q4 FY26 EBITDA surpassing INR200 crores. Full year FY26 revenue grew 13.8% to INR3,420 crores with EBITDA up 59.6% to INR702 crores and PAT jumping 14x to INR225 crores. Gross margins expanded 321 basis points to 54.3% due to strategic shift toward complex products and backward integration of APIs. Management highlighted successful integration post-merger, with synergies tracking ahead of the initial INR50-60 crore target toward INR125-150 crores. The company guided FY27 tax rate at 27% and expects to maintain current margin levels despite planned R&D investments for new product development, particularly in companion animals and oncology. The management also mentioned evaluating selective inorganic opportunities.
Strong operational performance with margin expansion signals execution capability. The company has achieved ahead-of-schedule targets and maintains a healthy balance sheet, positioning it well for sustained growth. Shareholders can expect continued focus on profitable growth with disciplined capital allocation.